Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00422591. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Trans
ClinicalTrials.gov study NCT00548847. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
ClinicalTrials.gov study NCT05252585. IPD Sharing: YES. Countries: 1. Publications: 0.
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
ClinicalTrials.gov study NCT01692197. IPD Sharing: Not stated. Countries: 1. Publications: 0.
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
ClinicalTrials.gov study NCT02440568. IPD Sharing: NO. Countries: 1. Publications: 0.
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00093990. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
ClinicalTrials.gov study NCT02532010. IPD Sharing: YES. Countries: 1. Publications: 0.
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
ClinicalTrials.gov study NCT05275439. IPD Sharing: NO. Countries: 3. Publications: 0.
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03154827. IPD Sharing: NO. Countries: 6. Publications: 0.
Epigenetic Reprogramming in Relapse/Refractory AML
ClinicalTrials.gov study NCT03263936. IPD Sharing: UNDECIDED. Countries: 3. Publications: 0.
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
ClinicalTrials.gov study NCT04081259. IPD Sharing: YES. Countries: 1. Publications: 0.
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT01662505. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03224819. IPD Sharing: YES. Countries: 3. Publications: 0.
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
ClinicalTrials.gov study NCT01838395. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
ClinicalTrials.gov study NCT05020665. IPD Sharing: NO. Countries: 12. Publications: 0.
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
ClinicalTrials.gov study NCT05583552. IPD Sharing: Not stated. Countries: 3. Publications: 0.
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03730012. IPD Sharing: NO. Countries: 1. Publications: 0.
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete
ClinicalTrials.gov study NCT03409081. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT01184898. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
ClinicalTrials.gov study NCT01690624. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.